PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

Status Completed

Clinical Trial Summary

Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.

Clinical Trial Description

A lack of oxygen (hypoxia) or low blood supply (ischaemia) before or during birth can destroy cells in a newborn baby's brain. The damage caused by the lack of oxygen continues for some time afterwards. One way to try to reduce this damage is to induce hypothermia cooling the baby or just the baby's head for hours to days. Erythropoietin (Epo) given in the first week after birth shows promise as a treatment that may also help. This study is to find out whether Epo plus induced hypothermia (cooling) of near-term newborn babies who have suffered from low blood or oxygen supply to the brain at birth reduces death and disability in survivors at two years of age. The target population is 300 newborn term or near term infants (greater than or equal to 35+0 weeks gestation) with hypoxic ischaemic encephalopathy who are receiving, or planned to receive hypothermia and who are able to be recruited in time to allow study treatment to commence before 24 hours of age. This is a double blind, placebo controlled, parallel, 2 arm randomised, phase III multicentre trial, stratified by study site and by severity of encephalopathy at study entry. The treatment group of 150 infants will receive human recombinant Epo, 1000 IU/kg IV on days 1, 2, 3, 5 & 7 of life. The control group will receive 0.9% sodium chloride as a placebo on days 1, 2, 3, 5 & 7 of life. Families will be followed up every 6 months until the primary assessment of death and disability at 2 years of age. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03079167
Study type	Interventional
Source	University of Sydney
Contact
Status	Completed
Phase	Phase 3
Start date	May 14, 2016
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05048550` - Babies in Glasses; a Feasibility Study.	N/A
Recruiting	`NCT05514340` - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy	Phase 2
Recruiting	`NCT05836610` - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates	Phase 4
Completed	`NCT03024021` - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed	`NCT01913340` - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)	Phase 1/Phase 2
Enrolling by invitation	`NCT02260271` - Florida Neonatal Neurologic Network
Terminated	`NCT01192776` - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)	N/A
Completed	`NCT06344286` - The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE	N/A
Recruiting	`NCT05901688` - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting	`NCT02894866` - Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy	N/A
Recruiting	`NCT03682042` - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up	N/A
Recruiting	`NCT03657394` - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries	N/A
Withdrawn	`NCT03681314` - Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU)	N/A
Completed	`NCT03485781` - Propofol-induced EEG Changes in Hypoxic Brain Injury
Not yet recruiting	`NCT06429007` - A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury	Phase 2
Recruiting	`NCT05568264` - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit	N/A
Not yet recruiting	`NCT06448780` - Dose Optimization of Caffeine for HIE	Phase 1
Completed	`NCT02264808` - Developmental Outcomes
Completed	`NCT05687708` - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia	N/A
Recruiting	`NCT06195345` - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns — PAEAN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms